Dr Rachel Harding
Editor
Toronto, Canada
Dr. Rachel Harding is a postdoctoral fellow in the lab of Prof. Cheryl Arrowsmith at the Structural Genomics Consortium (SGC) at the University of Toronto, Canada. Rachel completed both her undergraduate and DPhil at the University of Oxford where she trained in structural biology and protein biophysical chemistry. Rachel is interested in understanding what the huntingtin protein looks like and how it interacts with different molecules in our cells.
Articles edited by Dr Rachel Harding
- Drug to treat movement symptoms of HD approved by FDA
- PROOF-HD study of pridopidine ends with negative result
- Hunting for balance: how the huntingtin protein compensates in HD
- uniQure gets the green light to resume testing HD gene therapy
- Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Updates from uniQure about their gene therapy for Huntington's disease
- Revisiting vitamin therapy for HD
- Oral drug may change the story for huntingtin lowering
- Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
- KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
- Huntington's disease therapeutics conference 2021 - Day 3
- Huntington’s disease therapeutics conference 2021 - Day 1
- Huntington's disease therapeutics conference 2021 - Day 2
- Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
- Uncovering the dark side of DNA repair to design HD treatments
- When genes are unstable: targeting somatic instability in HD
- What does COVID-19 mean for Huntington’s disease families and HD research?
- New molecule can reverse the Huntington's disease mutation in lab models
Articles written by Dr Rachel Harding
- Tipping the balance; new insights into HD genetic modifiers
- Drug to treat movement symptoms of HD approved by FDA
- Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
- Huntington’s disease therapeutics conference 2023 - Day 3
- Start here!
- Huntington’s disease therapeutics conference 2023 - Day 2
- Huntington’s disease therapeutics conference 2023 - Day 1
- Roche Phase II GENERATION HD2 study underway
- Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
- Update on the PTC Therapeutics PIVOT-HD Trial
- Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
- Hereditary Disease Foundation (HDF) conference 2022 – Day 4
- Hereditary Disease Foundation (HDF) conference 2022 – Day 3
- Hereditary Disease Foundation (HDF) conference 2022 – Day 1
- Hereditary Disease Foundation (HDF) conference 2022 – Day 2
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
- Updates from uniQure about their gene therapy for Huntington's disease
- Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.
- Huntington’s disease therapeutics conference 2022 - Day 2
- Huntington’s disease therapeutics conference 2022 - Day 1
- A spoonful of branaplam helps the huntingtin go down
- Huntington’s disease therapeutics conference 2022 - Day 3
- Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
- Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
- “Seeing” the toxic huntingtin protein in people with HD
- Updates from the EHDN Meeting 2021
- Does blood hold the key to testing treatments earlier in HD patients?
- Scientists identify precisely how pridopidine works in models of Huntington’s disease
- Huntington's disease therapeutics conference 2021 - Day 3
- Huntington’s disease therapeutics conference 2021 - Day 1
- Huntington's disease therapeutics conference 2021 - Day 2
- Huntington’s disease clinical trial round up
- Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
- Sad News from Roche and Ionis - ASO Trial Halted Early
- Vaccines and HD
- GPR52: Exploring a new way to lower huntingtin
- Updates from the EHDN Plenary Meeting 2020
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1
- Treatment for neurological disorder could be repurposed for Huntington’s disease patients
- When genes are unstable: targeting somatic instability in HD
- Caution urged for the use of gene-editing technology CRISPR
- Fountain of youth: HTT protein repairs neurons by maintaining youthful state
- Huntington’s disease therapeutics conference 2020 - Day 1
- Huntington’s disease therapeutics conference 2020 - Day 3
- Huntington’s disease therapeutics conference 2020 - Day 2
- Screening the entire genome for new drug targets for HD